Cognitive function based on theta-gamma coupling vs. clinical diagnosis in older adults with mild cognitive impairment with or without major depressive disorder
© 2024. The Author(s)..
Whether individuals with mild cognitive impairment (MCI) and a history of major depressive disorder (MDD) are at a higher risk for cognitive decline than those with MCI alone is still not clear. Previous work suggests that a reduction in prefrontal cortical theta phase-gamma amplitude coupling (TGC) is an early marker of cognitive impairment. This study aimed to determine whether using a TGC cutoff is better at separating individuals with MCI or MCI with remitted MDD (MCI+rMDD) on cognitive performance than their clinical diagnosis. Our hypothesis was that global cognition would differ more between TGC-based groups than diagnostic groups. We analyzed data from 128 MCI (mean age: 71.8, SD: 7.3) and 85 MCI+rMDD (mean age: 70.9, SD: 4.7) participants. Participants completed a comprehensive neuropsychological battery; TGC was measured during the N-back task. An optimal TGC cutoff was determined during the performance of the 2-back. This TGC cutoff was used to classify participants into low vs. high-TGC groups. We then compared Cohen's d of the difference in global cognition between the high and low TGC groups to Cohen's d between the MCI and MCI+rMDD groups. We used bootstrapping to determine 95% confidence intervals for Cohen's d values using the whole sample. As hypothesized, Cohen's d for the difference in global cognition between the TGC groups was larger (0.64 [0.32, 0.88]) than between the diagnostic groups (0.10 [0.004, 0.37]) with a difference between these two Cohen's d's of 0.54 [0.10, 0.80]. Our findings suggest that TGC is a useful marker to identify individuals at high risk for cognitive decline, beyond clinical diagnosis. This could be due to TGC being a sensitive marker of prefrontal cortical dysfunction that would lead to an accelerated cognitive decline.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Translational psychiatry - 14(2024), 1 vom: 19. März, Seite 153 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brooks, Heather [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 21.03.2024 Date Revised 23.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41398-024-02856-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36993346X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36993346X | ||
| 003 | DE-627 | ||
| 005 | 20240323235407.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41398-024-02856-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1342.xml |
| 035 | |a (DE-627)NLM36993346X | ||
| 035 | |a (NLM)38503740 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brooks, Heather |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cognitive function based on theta-gamma coupling vs. clinical diagnosis in older adults with mild cognitive impairment with or without major depressive disorder |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2024 | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Whether individuals with mild cognitive impairment (MCI) and a history of major depressive disorder (MDD) are at a higher risk for cognitive decline than those with MCI alone is still not clear. Previous work suggests that a reduction in prefrontal cortical theta phase-gamma amplitude coupling (TGC) is an early marker of cognitive impairment. This study aimed to determine whether using a TGC cutoff is better at separating individuals with MCI or MCI with remitted MDD (MCI+rMDD) on cognitive performance than their clinical diagnosis. Our hypothesis was that global cognition would differ more between TGC-based groups than diagnostic groups. We analyzed data from 128 MCI (mean age: 71.8, SD: 7.3) and 85 MCI+rMDD (mean age: 70.9, SD: 4.7) participants. Participants completed a comprehensive neuropsychological battery; TGC was measured during the N-back task. An optimal TGC cutoff was determined during the performance of the 2-back. This TGC cutoff was used to classify participants into low vs. high-TGC groups. We then compared Cohen's d of the difference in global cognition between the high and low TGC groups to Cohen's d between the MCI and MCI+rMDD groups. We used bootstrapping to determine 95% confidence intervals for Cohen's d values using the whole sample. As hypothesized, Cohen's d for the difference in global cognition between the TGC groups was larger (0.64 [0.32, 0.88]) than between the diagnostic groups (0.10 [0.004, 0.37]) with a difference between these two Cohen's d's of 0.54 [0.10, 0.80]. Our findings suggest that TGC is a useful marker to identify individuals at high risk for cognitive decline, beyond clinical diagnosis. This could be due to TGC being a sensitive marker of prefrontal cortical dysfunction that would lead to an accelerated cognitive decline | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zomorrodi, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Blumberger, Daniel M |e verfasserin |4 aut | |
| 700 | 1 | |a Bowie, Christopher R |e verfasserin |4 aut | |
| 700 | 1 | |a Daskalakis, Zafiris J |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Corinne E |e verfasserin |4 aut | |
| 700 | 1 | |a Flint, Alastair J |e verfasserin |4 aut | |
| 700 | 1 | |a Herrmann, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Sanjeev |e verfasserin |4 aut | |
| 700 | 1 | |a Lanctôt, Krista L |e verfasserin |4 aut | |
| 700 | 1 | |a Mah, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Mulsant, Benoit H |e verfasserin |4 aut | |
| 700 | 1 | |a Pollock, Bruce G |e verfasserin |4 aut | |
| 700 | 1 | |a Voineskos, Aristotle N |e verfasserin |4 aut | |
| 700 | 1 | |a Rajji, Tarek K |e verfasserin |4 aut | |
| 700 | 0 | |a PACt-MD Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Mulsant, Benoit H |e investigator |4 oth | |
| 700 | 1 | |a Rajji, Tarek K |e investigator |4 oth | |
| 700 | 1 | |a Herrmann, Nathan |e investigator |4 oth | |
| 700 | 1 | |a Pollock, Bruce G |e investigator |4 oth | |
| 700 | 1 | |a Blumberger, Daniel M |e investigator |4 oth | |
| 700 | 1 | |a Bowie, Christopher R |e investigator |4 oth | |
| 700 | 1 | |a Butters, Meryl A |e investigator |4 oth | |
| 700 | 1 | |a Fischer, Corinne E |e investigator |4 oth | |
| 700 | 1 | |a Flint, Alastair J |e investigator |4 oth | |
| 700 | 1 | |a Golas, Angela |e investigator |4 oth | |
| 700 | 1 | |a Graff, Ariel |e investigator |4 oth | |
| 700 | 1 | |a Kennedy, James L |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Sanjeev |e investigator |4 oth | |
| 700 | 1 | |a Lanctôt, Krista L |e investigator |4 oth | |
| 700 | 1 | |a Lourenco, Lillian |e investigator |4 oth | |
| 700 | 1 | |a Mah, Linda |e investigator |4 oth | |
| 700 | 1 | |a Ovaysikia, Shima |e investigator |4 oth | |
| 700 | 1 | |a Rapoport, Mark |e investigator |4 oth | |
| 700 | 1 | |a Thorpe, Kevin E |e investigator |4 oth | |
| 700 | 1 | |a Verhoeff, Nicolaas P L G |e investigator |4 oth | |
| 700 | 1 | |a Voineskos, Aristotle |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Translational psychiatry |d 2011 |g 14(2024), 1 vom: 19. März, Seite 153 |w (DE-627)NLM209970901 |x 2158-3188 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:19 |g month:03 |g pages:153 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41398-024-02856-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 19 |c 03 |h 153 | ||